ClinicalTrials.gg
CompletedNCT00806416Updated Feb 8, 2022Results posted

A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D

A Phase 1 interventional study of alendronate sodium (+) cholecalciferol and Comparator: alendronate in Osteoporosis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-08.

Sponsored by Organon and Co · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.

Enrollment
8th of 51
244 · median 60
Started
2003
with 4 others
Phase 1
2 of 51
none open now
Registered
28th of 51
by date
Lead sponsor
2 of 51
Organon and Co

Among the 51 studies testing alendronate in Osteoporosis, this one is the 8th largest by enrollment, is one of 5 that started in 2003, is one of 2 in phase 1, and was the 28th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alendronate

Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing alendronate in Osteoporosis, or all of them as a file.
02

Study summary

This study will evaluate the bioequivalence of alendronate in combination with vitamin D (cholecalciferol) compared to alendronate alone and the bioequivalence of vitamin D in combination with alendronate compared to vitamin D alone.

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or nonpregnant female age 18 to 65 years
  • Female of on appropriate method of and not nursing
  • (body mass index) less than or equal to 30 kg/m2
  • Subject is in good health
  • Willing to limit direct sunlight and apply sunscreen if in the sun more than 1 hour

Exclusion criteria

Exclusion Criteria:

  • mental or legal incapacitation
  • received bisphosphonate treatment within 3 months of screening
  • unable to sit or stand upright for at least 2 hours
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Sequence 1

    alendronate/vitamin D combination then alendronate

    Drug: alendronate sodium (+) cholecalciferol · Drug: Comparator: alendronate

  • Experimental
    Sequence 2

    alendronate then alendronate/vitamin D combination

    Drug: alendronate sodium (+) cholecalciferol · Drug: Comparator: alendronate

  • Experimental
    Sequence 3

    alendronate/vitamin D combination then vitamin D

    Drug: alendronate sodium (+) cholecalciferol · Dietary Supplement: Comparator: cholecalciferol (Vitamin D)

  • Experimental
    Sequence 4

    vitamin D then alendronate/vitamin D combination

    Drug: alendronate sodium (+) cholecalciferol · Dietary Supplement: Comparator: cholecalciferol (Vitamin D)

Interventions

  • Drugalendronate sodium (+) cholecalciferol

    A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

  • A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

  • A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.

06

What researchers measure

Primary outcomes

  1. Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet

    Urinary excretion of alendronate was determined over a 36-hour period following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 70 mg alendronate alone tablet. Urine for each treatment period was collected at -2 to 0 hours predose, 0 to 8, 8 to 24, and 24 to 36 hours postdose.

    Time frame: On Day 1 across the 36-hour urinary collection period (Periods 1 and 2).

  2. Part II : The Pharmacokinetic Parameters AUC0-120 hr of Vitamin D in Combination Tablet Relative to Vitamin D Tablet

    Serum vitamin D3 pharmacokinetic parameter AUC0-120 hr (area under the serum concentration-time curve) after treatment on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.

    Time frame: On Day 1 across the 120-hour plasma collection period (Periods 1 and 2).

  3. Part II : The Pharmacokinetic Parameters Cmax of Vitamin D in Combination Tablet Relative to Vitamin D Tablet

    Serum vitamin D3 pharmacokinetic parameter Cmax (maximum concentration observed in serum) after treatmen on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.

    Time frame: On Day 1 across the 120-hour plasma collection period (Periods 1 and 2).

07

Results

Posted Feb 12, 2010

Participant flow

Participants were recruited from the following clinical research organizations: Thomas Jefferson University, Division of Clinical Pharmacology, Philadelphia, PA; Clinical Pharmacology Associates, Miami, FL; and Northwest Kinetics, Tacoma, WA, between May 2003 and July 2003.

Period 1 - Part I
Participant flow — Period 1 - Part I
MilestoneAlendronate/Vitamin D Combination Then AlendronateAlendronate Then Alendronate/Vitamin D CombinationAlendronate/Vitamin D Combination Then Vitamin DVitamin D Then Alendronate/Vitamin D Combination
Started10710700
Completed10410300
Not completed3400
Withdrew: Adverse event0100
Withdrew: Lost to follow-up0200
Withdrew: Withdrawal by subject3100
Period 2 - Part I
Participant flow — Period 2 - Part I
MilestoneAlendronate/Vitamin D Combination Then AlendronateAlendronate Then Alendronate/Vitamin D CombinationAlendronate/Vitamin D Combination Then Vitamin DVitamin D Then Alendronate/Vitamin D Combination
Started10410300
Completed10410300
Not completed0000
Period 1 - Part II
Participant flow — Period 1 - Part II
MilestoneAlendronate/Vitamin D Combination Then AlendronateAlendronate Then Alendronate/Vitamin D CombinationAlendronate/Vitamin D Combination Then Vitamin DVitamin D Then Alendronate/Vitamin D Combination
Started001416
Completed001414
Not completed0002
Withdrew: Withdrawal by subject0002
Period 2 - Part II
Participant flow — Period 2 - Part II
MilestoneAlendronate/Vitamin D Combination Then AlendronateAlendronate Then Alendronate/Vitamin D CombinationAlendronate/Vitamin D Combination Then Vitamin DVitamin D Then Alendronate/Vitamin D Combination
Started001414
Completed001414
Not completed0000

Outcome measures

PrimaryPart 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet

Urinary excretion of alendronate was determined over a 36-hour period following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 70 mg alendronate alone tablet. Urine for each treatment period was collected at -2 to 0 hours predose, 0 to 8, 8 to 24, and 24 to 36 hours postdose.

Time frame:
On Day 1 across the 36-hour urinary collection period (Periods 1 and 2).
Reported as:
Least squares mean · micrograms (μg)
Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet
micrograms (μg)Alendronate/Vitamin D CombinationAlendronate
Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet197.5 ± 329.1191.9 ± 522.2
Statistical analysis
  • Alendronate/Vitamin D Combination vs Alendronate · Least square mean ratio: 1.03 · 90% CI 0.91 to 1.17
PrimaryPart II : The Pharmacokinetic Parameters AUC0-120 hr of Vitamin D in Combination Tablet Relative to Vitamin D Tablet

Serum vitamin D3 pharmacokinetic parameter AUC0-120 hr (area under the serum concentration-time curve) after treatment on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.

Time frame:
On Day 1 across the 120-hour plasma collection period (Periods 1 and 2).
Reported as:
Least squares mean · ng*hr/mL
Part II : The Pharmacokinetic Parameters AUC0-120 hr of Vitamin D in Combination Tablet Relative to Vitamin D Tablet
ng*hr/mLAlendronate/Vitamin D CombinationVitamin D
Part II : The Pharmacokinetic Parameters AUC0-120 hr of Vitamin D in Combination Tablet Relative to Vitamin D Tablet296.4 ± 375.5337.9 ± 344.2
Statistical analysis
  • Alendronate/Vitamin D Combination vs Vitamin D · Least square mean ratio for auc0-120 hr: 0.88 · 90% CI 0.81 to 0.95
PrimaryPart II : The Pharmacokinetic Parameters Cmax of Vitamin D in Combination Tablet Relative to Vitamin D Tablet

Serum vitamin D3 pharmacokinetic parameter Cmax (maximum concentration observed in serum) after treatmen on Day 1was calculated following single-dose administration of a 70 mg alendronate/2800-IU vitamin D3 combination tablet or 2800-IU vitamin D3 tablet. Serum for each treatment period was collected at -24, -18, -12, -6, and 0 hours predose, and 2, 3, 5, 7, 9, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose.

Time frame:
On Day 1 across the 120-hour plasma collection period (Periods 1 and 2).
Reported as:
Least squares mean · ng/mL
Part II : The Pharmacokinetic Parameters Cmax of Vitamin D in Combination Tablet Relative to Vitamin D Tablet
ng/mLAlendronate/Vitamin D CombinationVitamin D
Part II : The Pharmacokinetic Parameters Cmax of Vitamin D in Combination Tablet Relative to Vitamin D Tablet5.9 ± 3.36.6 ± 3.1
Statistical analysis
  • Alendronate/Vitamin D Combination vs Vitamin D · Least-squares mean for cmax: 0.89 · 90% CI 0.84 to 0.95

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alendronate/Vitamin D Combination—0/240 (0%)55/240 (22.9%)
Alendronate—0/214 (0%)39/214 (18.2%)
Vitamin D—0/30 (0%)9/30 (30%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventAlendronate/Vitamin D CombinationAlendronateVitamin D
HeadacheNervous system disorders30/24020/2143/30
DiarrhoeaGastrointestinal disorders9/2406/2141/30
ConjunctivitisEye disorders1/2400/2141/30
NauseaGastrointestinal disorders4/2404/2141/30
InjuryInjury, poisoning and procedural complications0/2400/2141/30
Haemoglobin DecreasedInvestigations1/2400/2141/30
White Blood Cells Urine PositiveInvestigations0/2400/2141/30
Muscle CrampMusculoskeletal and connective tissue disorders0/2400/2141/30
VomitingGastrointestinal disorders5/2403/2140/30
DyspepsiaGastrointestinal disorders3/2404/2140/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part IPart IITotal
Mean41.6 (18 to 65)35.2 (19 to 54)40.8 (18 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Part IPart IITotal
Female11914133
Male9516111
Height
Height(Centimeters)Part IPart IITotal
Mean167.2 (144.8 to 190.5)170.4 (156.2 to 190.5)167.5 (144.8 to 190.5)
Weight
Weight(Kilograms)Part IPart IITotal
Mean72.8 (48.0 to 105.4)71.2 (49.9 to 98.4)72.6 (48.0 to 105.4)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Denker AE, Lazarus N, Porras A, Ramakrishnan R, Constanzer M, Scott BB, Chavez-Eng C, Woolf E, Maganti L, Larson P, Gottesdiener K, Wagner JA. Bioavailability of alendronate and vitamin D(3) in an alendronate/vitamin D(3) combination tablet. J Clin Pharmacol. 2011 Oct;51(10):1439-48. doi: 10.1177/0091270010382010. Epub 2010 Dec 8. PubMed 21148044 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Aug 2003 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2008
First posted
Dec 10, 2008
Start
May 2003
Primary completionActual
Aug 2003
CompletionActual
Jan 2004
Results first posted
Feb 12, 2010
Last update
Feb 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00806416
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 10, 2008
Start date
May 2003
Primary completion
Aug 2003
Completion
Jan 2004
Results posted
Feb 12, 2010
Last update
Feb 8, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alendronate · Cholecalciferol

Start the discussion